Supernus Pharmaceuticals has signed a big agreement for a $650 million loan linked to its merger with Indivior.

Nov 2, 2026, 9:29 AM ETDealRead the original at SEC EDGAR

Neutral

Supernus completed a merger that gives each eligible share 1.5401 Indivior shares. The combined company also borrowed $650 million against its property, but the filing does not show whether the exchange benefits former Supernus holders.

SUPN · Supernus Pharmaceuticals, Inc.

AI read · Neutral

The AI's read

Former Supernus owners now hold Indivior shares, so their fortunes depend on the combined company. The $650 million loan adds interest payments, claims on company property, and limits on some actions. The filing gives no comparison of the shares' value or expected business results, so it does not show a clear benefit or harm to former Supernus holders.

Get alerts for SUPN

Follow Supernus Pharmaceuticals, Inc. (SUPN) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for SUPN

Free on the App Store and Google Play, or on the web.